DK1242452T3 - Kimære natriuretiske peptider - Google Patents

Kimære natriuretiske peptider

Info

Publication number
DK1242452T3
DK1242452T3 DK00988092T DK00988092T DK1242452T3 DK 1242452 T3 DK1242452 T3 DK 1242452T3 DK 00988092 T DK00988092 T DK 00988092T DK 00988092 T DK00988092 T DK 00988092T DK 1242452 T3 DK1242452 T3 DK 1242452T3
Authority
DK
Denmark
Prior art keywords
natriuretic peptides
chimeric natriuretic
peptides
chimeric
natriuretics
Prior art date
Application number
DK00988092T
Other languages
English (en)
Inventor
John Burnett Jr
Ondrej Lisy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of DK1242452T3 publication Critical patent/DK1242452T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00988092T 1999-12-17 2000-12-15 Kimære natriuretiske peptider DK1242452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/466,268 US6407211B1 (en) 1999-12-17 1999-12-17 Chimeric natriuretic peptides
PCT/US2000/034080 WO2001044284A2 (en) 1999-12-17 2000-12-15 Chimeric natriuretic peptides

Publications (1)

Publication Number Publication Date
DK1242452T3 true DK1242452T3 (da) 2007-06-11

Family

ID=23851133

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00988092T DK1242452T3 (da) 1999-12-17 2000-12-15 Kimære natriuretiske peptider

Country Status (11)

Country Link
US (4) US6407211B1 (da)
EP (1) EP1242452B1 (da)
JP (1) JP5031964B2 (da)
AT (1) ATE353916T1 (da)
AU (1) AU2433901A (da)
CA (1) CA2395585C (da)
DE (1) DE60033431T2 (da)
DK (1) DK1242452T3 (da)
ES (1) ES2282160T3 (da)
PT (1) PT1242452E (da)
WO (1) WO2001044284A2 (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2003081246A1 (en) * 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
WO2004022003A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
EP1569683B1 (en) 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
WO2004097368A2 (en) * 2003-04-28 2004-11-11 Ciphergen Biosystems, Inc. Improved immunoassays
DK1638443T3 (da) 2003-06-20 2011-02-07 Mayo Foundation Isoformer af hjerne-natriuretisk peptid
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) * 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
EP1773867B1 (en) 2004-07-15 2011-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
AT500800B1 (de) * 2004-09-08 2008-07-15 Biomedica Medizinprodukte Gmbh Verfahren zur bestimmung von probnp
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) * 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
ES2554713T3 (es) 2005-04-07 2015-12-22 Cardiorentis Ag Uso de un péptido natriurético para tratar insuficiencia cardiaca
WO2007035600A2 (en) * 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
DK2001518T3 (da) 2006-03-30 2013-10-07 Palatin Technologies Inc Cykliske natriuretiske peptidfremstillinger
EP2051585A4 (en) * 2006-04-28 2010-06-02 Univ South Florida MATERIALS AND METHODS OF SUPPRESSING INFLAMMATION THROUGH INHIBITION OF THE VORHOF RECEPTOR FOR NATRIURETIC PEPTIDES
MX2009001459A (es) * 2006-08-08 2009-02-19 Mayo Foundation Polipeptidos diureticos y natriureticos.
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CN101600731A (zh) * 2006-09-08 2009-12-09 梅约医学教育与研究基金会 不具备血管舒张活性的促排水和利尿钠多肽
WO2008092019A1 (en) * 2007-01-25 2008-07-31 Mayo Foundation For Medical Education And Research Fgf-23 polypeptides
PT2765139T (pt) 2007-07-20 2017-07-14 Mayo Foundation Polipéptidos natriuréticos
WO2009036448A2 (en) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
WO2009055644A2 (en) * 2007-10-24 2009-04-30 California Institute Of Technology Methods using the grueneberg ganglion chemosensory system
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
CA2727085A1 (en) * 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
US20110206633A1 (en) * 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US8642550B2 (en) * 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120053123A1 (en) * 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
HUE032582T2 (en) * 2009-05-20 2017-09-28 Biomarin Pharm Inc Variants of C-type natriuretic peptide
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US20120208756A1 (en) * 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
US8778699B2 (en) 2010-08-04 2014-07-15 Idexx Laboratories, Inc. Detection of degradation products of canine NT-proBNP
EP2632477A2 (en) 2010-10-29 2013-09-04 Nile Therapeutics, Inc. Methods of treatment with natriuretic peptides
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
BR112013018679B1 (pt) 2011-01-21 2022-04-12 Igisu Co. Ltd. Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2715353B1 (en) 2011-05-31 2016-08-24 IDEXX Laboratories, Inc. DETECTION OF DEGRADATION PRODUCTS OF FELINE NT-proBNP
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
US20130244937A1 (en) 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2013070741A1 (en) * 2011-11-11 2013-05-16 Mayo Foundation For Medical Education And Research Methods and materials for regulating natriuretic polypeptide function
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
EP2833957A4 (en) * 2012-04-02 2016-03-09 Capricor Therapeutics Inc THERAPY FOR CHILDREN'S DISEASE AND / OR HEART FAILURE THROUGH INTRADERMAL INFUSION
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US8835601B2 (en) * 2012-12-21 2014-09-16 Mayo Foundation For Medical Education And Research Natriuretic polypeptide delivery systems
EP2948165A2 (en) * 2013-01-25 2015-12-02 Cardiorentis Ltd. A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
WO2014209229A1 (en) * 2013-06-25 2014-12-31 National University Of Singapore Vasodilation peptides and uses thereof
US9863900B2 (en) 2014-01-28 2018-01-09 Transtech Systems, Inc. Planar sensor array for non-destructive evaluation of material using electromagnetic impedance
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10161893B2 (en) 2014-08-19 2018-12-25 Transtech Systems, Inc. Characterization of material under test (MUT) with electromagnetic impedance spectroscopy
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US20180066020A1 (en) 2015-05-29 2018-03-08 Igisu Co., Ltd. A cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
SG10202101479PA (en) 2016-08-18 2021-03-30 Nat Univ Singapore Peptides with vasodilatory and/or diuretic functions
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (da) * 1974-03-08 1982-06-04
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4161521A (en) * 1975-08-08 1979-07-17 Merck & Co., Inc. Somatostatin analogs
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757048A (en) * 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4804650A (en) * 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) * 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
DK0914344T3 (da) 1996-03-04 2005-08-29 Scios Inc Assay og reagenser til kvantificering af hBNP
US5848956A (en) * 1997-03-18 1998-12-15 Grettner; Norman L. Multi-purpose lat sling
WO1999012576A2 (en) * 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
WO2000071576A2 (en) * 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Also Published As

Publication number Publication date
US20030069186A1 (en) 2003-04-10
JP5031964B2 (ja) 2012-09-26
DE60033431D1 (de) 2007-03-29
US20050059600A1 (en) 2005-03-17
JP2003517005A (ja) 2003-05-20
WO2001044284A2 (en) 2001-06-21
ES2282160T3 (es) 2007-10-16
US20020082219A1 (en) 2002-06-27
ATE353916T1 (de) 2007-03-15
US7964564B2 (en) 2011-06-21
PT1242452E (pt) 2007-05-31
US20090170756A1 (en) 2009-07-02
DE60033431T2 (de) 2007-11-29
US6407211B1 (en) 2002-06-18
US6818619B2 (en) 2004-11-16
EP1242452B1 (en) 2007-02-14
EP1242452A2 (en) 2002-09-25
CA2395585A1 (en) 2001-06-21
WO2001044284A3 (en) 2002-01-31
CA2395585C (en) 2014-09-09
US7384917B2 (en) 2008-06-10
AU2433901A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
DK1242452T3 (da) Kimære natriuretiske peptider
DE69934345D1 (de) Selbstfüllender, nadelfreier Y-Adapter
MXPA03007319A (es) Anticuerpos contra egfr modificados, con inmunogenicidad reducida.
EP1553975A4 (en) OPTIMIZED FC VARIANTS AND MANUFACTURING METHOD THEREFOR
TR199801351A3 (tr) Yapi elemanlarinin takviyesi için yöntem.
DE50114428D1 (de) Neue verwendung von kurzkettigen carbonsäuren
ID23374A (id) Halogenopirimidin
NO983244D0 (no) 5H-Tiazolo £3,2-a| pyrimidinderivater
NL1010890C2 (nl) Stabilisatormengsel.
IT1319958B1 (it) Vasca di fermentazione.
BR9916507A (pt) Proteìnas
BR0115125B1 (pt) acendedor.
AR010362A1 (es) UN GEN QUIMÉRICO, UN MICROORGANISMO MODIFICADO TRANSFORMADO CON EL GEN QUIMÉRICO, UN PLÁSMIDO, UN MICROORGANISMO MODIFICADO TRANSFORMADO CON EL PLÁSMIDO, MÉTODO DE MODIFICACION METABOLOLICA, MÉTODO DE PRODUCCIoN DE UNA PROTEíNA DE RAFINOSA SINTASA AISLADA Y UN ANTICUERPO ANTI-RAFINOSA SINTETASA.
PE20399A1 (es) Muteina ob
DE59106119D1 (de) Stabilisatorkombinationen und ihre Verwendung zur Herstellung von stabilisierten, schlagzähmodifizierten Polyamiden.
Pagāre Gandharvasena
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
IT1317304B1 (it) Trefolo per la tessitura di tele per la costruzione di manufatti.
ES1044233Y (es) Calzado convertible.
WO2001044287A3 (en) Novel polypeptides and nucleic acids encoding same
ITTO960044A0 (it) Orizzontamento autoportante di tipo reticolare-spaziale per costruzioni civili, industriali, rurali.
ITBO20000414A0 (it) Valvola cardiaca .
IT1311090B1 (it) Isola artificiale metallica, galleggiante, mobile, autolivellante,inaffondabile.
ITNO20000004A1 (it) Termodinamo elettrochimica.
ES1042178Y (es) Soporte de agarre manual, transformable.